ARTICLE | Finance
Ebb & Flow
September 18, 2006 7:00 AM UTC
When Amicus pulled its proposed IPO in July, the genetic disease company was hardly hurting for cash, as it had about $40 million in the bank. Nevertheless, Amicus was clearly ready to listen when existing investor New Enterprise Associates suggested a giant private round.
The result was last week's $60 million series D round, in which NEA put in half the money. Indeed, only one new investor - Och-Ziff Capital Management - joined existing investors Canaan Partners; CHL Medical Partners; Frazier Healthcare Ventures; Palo Alto Investors; Prospect Venture Partners; Quaker BioVentures; and Radius...